Argenx Shares Hit 52-Week High After Positive Vyvgart Hytrulo Trial Results
By Chris Wack
Argenx shares were up 30% to $492.01 Monday after the immunology company said it saw positive topline results from its study with biopharmaceutical company Zai Lab evaluating Vyvgart Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with chronic inflammatory demyelinating polyneuropathy.
Argenx stock hit its 52-week high of $498.63 earlier in the session and is up 35% over the past 12 months. Zai Lab shares were up 8% to $30.17.
The companies said the study met its primary endpoint, demonstrating a significantly lower risk of relapse with Vyvgart Hytrulo compared with placebo.
The study showed that the safety and tolerability profile was consistent with the confirmed safety profile of Vyvgart, and 91% of eligible patients continued to the next phase of the open-label extension study.
The most frequent treatment-related adverse event was injection site reactions, which occurred in a lower percentage of patients than previous Vyvgart Hytrulo trials. All injection site reactions were mild to moderate and resolved over time.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 17, 2023 10:49 ET (14:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?